RS-2024-00332252

Study on the deriving of oHSV-1 candidate for an immunotherapeutic targeting to the ovarian cancer

Gencellmed Inc.

Gencellmed

ONCOLOGY | **Candidate**

Product Type	Oncolytic herpes simplex virus 1
Indication	Ovarian cancer
Target	Epithelial Cell Adhesion Molecule (EpCAM)
MoA(Mechanism of Action)	• Specific-targeting to tumor-associated antigens (TAAs) by binding to the bi-specific adapter and the chimeric gH (Cancer cell-specific infection) • Induction of a systemic anticancer effect by boosting the immune system through cytokines directly expressed from oHSV • Cancer-selective viral genome replication (pTERT-ICP6) and neurovirulence-defeciency (LAT deletion and UL56 gene truncation) 
Competitiveness	• Most competitor products in clinical trials are attenuated to various degrees, obtaining cancer specificity through attenuation. A potential drawback of these attenuated oHSVs is their less efficient replication, leading to lower viral production. In sharp contrast, GCM oHSV-1 has been developed to retarget HSV tropism to EpCAM while preserving full lytic potential. • GCM oHSV-1 exclusively infects EpCAM-expressing cells, selectively replicating in cancer cells and avoiding replication in normal cells, ensuring high level of safety. • In addition, the insertion of cytokine genes induces a robust systemic antitumor immune response.
Development Stage	Candidate
Route of Administration	Intratumoral, intravenous, and intraperitoneal administration

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund